Close

What are ADC's

Our services

ADC Review
is made possible by:




SYD985 | trastuzumab vc-seco-DUBA | NCT02277717 (Clinical Trial)

Study Title
First-in-human Study With the Antibody-drug Conjugate SYD985 to Evaluate Safety and Efficacy in Cancer Patients. NCT02277717

Trial Description
The purpose of this study is to evaluate the safety of a new medicinal drug SYD985 at different dose levels in patients with cancer, to understand how SYD985 is handled by the body and to evaluate the effect of SYD985 on the cancer.

This trial is sponsored by Synthon Biopharmaceuticals® BV

Study Data

  • Condition: Solid Tumors
  • Interventions:
  • Phase: I
  • Estimated Enrollment: 160
  • Start: October 2014
  • Estimated Completion: December 2018
  • Last verified: January 2018

Study Schematic

NCT02277717

Click here to Return to Drug map


Last Editorial review: February 2018
Information based on ClinicalTrials.gov (NIH/NCI) and other sources.

Copyright © 2015-2018 InPress Media Group. All rights reserved. Republication or redistribution of InPress Media Group content, including by framing or similar means, is expressly prohibited without the prior written consent of InPress Media Group. InPress Media Group shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon. ADC Review / Journal of Antibody-drug Conjugates is a registered trademarks and trademarks of InPress Media Group around the world.

Add to Flipboard Magazine.


Share

Recommended Articles

Four Ways to Show Nonobviousness of ADC Inventions

05 October, 2018

When the first antibody-drug conjugate (ADC) was approved by the U.S. Food and Drug Administration (FDA) in 2000,[1] only a handful of patent applications claiming ADCs had been published.[2] As research cont...


Skip to toolbar